Stock AnalizErasca, Inc. ERAS
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Erasca, Inc. (ERAS) is a healthcare company listed in the US with a market value of about $5.5B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -34%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$125M | -$162M | -$125M | -$243M | -$123M | -$102M |
| Free cash flow | -$96M | -$109M | -$103M | -$118M | -$91M | -$34M |
| EPS (diluted) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 | $-4.83 |
| Net margin | — | — | — | — | — | — |
| ROIC | -37.9% | -37.8% | -30.0% | -41.9% | -20.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $24.11, 54% above the current price; targets range from $20.00 to $33.00; the consensus rating is “Buy”; expected EPS is $-1.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Erasca pay a dividend?
Not currently.
Is Erasca a good stock to buy?
We do not give buy or sell advice. Erasca scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.